Anticoagulant effect of Huisheng oral solution in a rat model of thrombosis

Indian Journal of Pharmacology

Volumn 45, Issue 4, 2013, Pages 359-364

  Liu, Shuang Qing ^a   Guo, Jian Ying ^a   Du, Jun ^b   Deng, Qun ^a   He, Zhong Jie ^a   Lin, Hong Yuan ^a   Lei, Shu Hong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Chengdu Diaotianfu Pharm   (China)

Author keywords

Fibrinolysis; Huisheng Oral Solution; hypercoagulable state; microthrombus; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; CARRAGEENAN; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HUISHENG ORAL SOLUTION; PROTHROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HISTOPATHOLOGY; INTERNATIONAL NORMALIZED RATIO; LIVER; LUNG; MALE; MEASUREMENT; MESENTERY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAT; THROMBOCYTE; THROMBOSIS;

FIBRINOLYSIS; HUISHENG ORAL SOLUTION; HYPERCOAGULABLE STATE; MICROTHROMBUS; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CARRAGEENAN; DRUGS, CHINESE HERBAL; FIBRINOLYSIS; LIVER; LUNG; MALE; MESENTERY; PLANT PREPARATIONS; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

EID: 84881446221     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.115018     Document Type: Article

References (26)

1. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-48.
2. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: From molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(Suppl 1):246-54.
3. Andreasen EB, Tranholm M, Wiinberg B, Markussen B, Kristensen AT. Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. Acta Vet Scand 2012;54:3.
4. Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107(23 Suppl 1):I17-21.
5. Fu J. Huisheng Oral Solution: Pharmacology and clinical applications. Shandong Med J 2011;51:110-1.
6. Gupta PK, Charan VD, Kumar H. Cancer related thrombophilia: Clinical importance and management strategies. Assoc Physicians India 2005;53:877-82.
7. Wang Z, Fu J, Diao D, Dang D.Plasma D-dimer level in the perioperative period in non-small-cell lung cancer. Thoracic Cancer 2011;2:207-12.
8. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-34.
9. van Marion AM, Auwerda JJ, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG, et al. Hypo-fibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005;94:1341-3.
10. Nurwidya F,Takahashi F,Takahashi K.Meeting report: Current cancer perspectives from the 9th Annual Meeting of the Japanese Society of Medical Oncology.Thoracic Cancer 2012;3:94-7.
11. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectalcancer. Thromb Haemost 2007;97:119-23.
12. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11:237-48.
13. Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602.
14. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-6.
15. Vilar Saavedra P, Lara García A, Zaldívar López S, Couto G. Hemostatic abnormalities in dogs with carcinoma: A thromboelastographic characterization of hypercoagulability. Vet J 2011;190:e78-83.
16. Yuan KF, Liao XM, Yu L, Niu T, Zhang XL, Liu WP, et al. Effects of urokinase intervention on endotoxin-induced DIC in Wistar rat model. Sichuan Da Xue Xue Bao Yi Xue Ban 2010;41:965-9.
17. Ducloy-Bouthors AS. Clotting disorders and preeclampsia. Ann Fr Anesth Reanim 2010;29:e121-34.
18. Machida T, Kokubu H, Matsuda K, Miyoshi K, Uchida E. Clinical use of D-dimer measurement for the diagnosis of disseminated intravascular coagulation in dogs. J Vet Med Sci 2010;72:1301-6.
19. Huang GJ, Wang XM, Mao XY, Du ZT. An experimental study of antitumor effects of Huisheng Oral Solution. Chin Tradit Patent Med 1998;20:37-9.
20. Ma D, Lin P, Deng G. Influence on Hui-sheng oral liquid to cellular immunity function of aged cancer patients after chemotherapy. J Chengdu Univ Tradit Chin Med 2005;28:52-4.
21. Yin ZS, Zhang LY, Xu LN. Effect of angelica and its active ingredient ferulic acid on platelet aggregation and 5-HT release in rats. Acta Pharm Sin 1980;15:321-6.
22. Zhang CF, Zhu XM, Gong B, Mo QZ, Li CZ, Yang SC. Investigation of mechanisms underlying anti-platelet aggregation effect of motherwort. J Chin Integr Med 1986;6:39-40.
23. Liu Y, Chen G,Qiu X, Chen J, Zhou Q.The 12th National Lung Cancer Academic Conference in China.Thoracic Cancer 2012;3:287-8.
24. Zou XY. Treatment of hemorrhagic stroke with leech and rhubarb: An analysis of 17 cases. J Pract Tradit Chin Intern Med 1994;8:26-7.
25. Zhao JM, Qin WY, Qi Y, Chen H, Song DF, Liu H. Anticoagulant activity of carithamine and its effect on platelet aggregation. Lab Anim Sci 2009;26:30-2.
26. Kongkam P, Devereaux BM, Ponnudurai R, Ratanachu-ek T, Sahai AV, Gotoda T. et al. Endoscopic Ultrasound Forum Summary from the Asian Pacific Digestive Week 2012. Endosc Ultras 2012;2:43-60.